Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated machine learning and molecular dynamics-driven multi-target virtual screening of FDA-approved drugs for drug repurposing in breast cancer.

In silico pharmacology·2026
Same author

Sulfonamide Derivatives as Competitive Lactoperoxidase Inhibitors Through Integrated Experimental and Multi-Level Computational Analysis.

Journal of biochemical and molecular toxicology·2026
Same author

Decoding PI3K isoform selectivity through an ensemble-based framework integrating correlated motions, allosteric networks, and hydration thermodynamics.

Journal of biomolecular structure & dynamics·2026
Same author

Thermodynamic Preference of Fe<sup>2+</sup> for a C-Terminal Coordination Site in Human Frataxin Revealed by Multiscale Simulations.

Journal of chemical information and modeling·2026
Same author

Shared molecular mechanisms in aging and neurodegenerative diseases: from mechanistic insights to therapeutic strategies.

Frontiers in human neuroscience·2026
Same author

Systems pharmacology approaches to modeling immune training and tolerance.

Current opinion in pharmacology·2026

Related Experiment Video

Updated: Jul 19, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K

Data mining and molecular dynamics analysis to detect HIV-1 reverse transcriptase RNase H activity inhibitor.

Naeem Abdul Ghafoor1, Kevser Kübra Kırboğa2,3, Ömür Baysal4

  • 1Department of Molecular Biology and Genetics, Faculty of Science, Muğla Sıtkı Koçman University, Kötekli, 48121, Muğla, Turkey.

Molecular Diversity
|August 10, 2023
PubMed
Summary

Researchers identified a new potential drug candidate, Phomoarcherin B, to inhibit HIV-1 replication by targeting the reverse transcriptase enzyme's RNase H activity. Further testing is needed to confirm its effectiveness against the human immunodeficiency virus.

Keywords:
Computational biologyDrug discoveryHIV-1Molecular dockingMolecular dynamicsPol geneReverse-transcriptase RNase H

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K
Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.0K

Related Experiment Videos

Last Updated: Jul 19, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K
Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.0K

Area of Science:

  • Virology
  • Drug Discovery
  • Computational Biology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) remains a significant global health challenge, necessitating novel therapeutic strategies.
  • Targeting essential viral proteins with conserved functions offers a promising avenue for developing effective antiviral agents.
  • The reverse transcriptase (R.T) enzyme's RNase H activity is crucial for HIV-1 replication and presents a potential drug target due to its conserved nature.

Purpose of the Study:

  • To identify a novel drug candidate capable of inhibiting HIV-1 replication.
  • To explore the RNase H activity of the HIV-1 reverse transcriptase as a therapeutic target.
  • To screen for small molecules that can effectively inhibit this specific viral activity.

Main Methods:

  • Utilized data mining and molecular dynamics simulations on HIV-1 genomes.
  • Performed MAUVE analysis to identify conserved and low-mutation targets within HIV-1.
  • Conducted virtual screening of approximately 94,000 small molecule inhibitors.
  • Validated hit compounds using molecular dynamics simulations and MM/PBSA for stability and binding free energy assessment.

Main Results:

  • The RNase H activity of the reverse transcriptase (R.T) enzyme was identified as a highly conserved and suitable target.
  • Phomoarcherin B, a compound with known anticancer properties, was identified as the most promising inhibitor candidate.
  • Molecular dynamics simulations and MM/PBSA confirmed the stability and favorable binding free energy of Phomoarcherin B.

Conclusions:

  • This study presents Phomoarcherin B as a potential new drug candidate for inhibiting HIV-1 replication by targeting reverse transcriptase RNase H activity.
  • The identified target and drug candidate offer a novel approach for HIV-1 treatment strategies.
  • Further in vitro and in vivo studies are essential to validate the efficacy and safety of Phomoarcherin B, alongside investigations into its broader effects on viral replication and interactions with other HIV-1 proteins.